N/A
N=58
Speech, Linguistic and Acoustic Markers in Parkinson's Disease
Parkinson Disease · Cognitive Impairment, Mild · Speech
Bottom Line
View on ClinicalTrials.gov: NCT04273672 ↗Enrolled (actual)
58
Serious AEs
0.0%
Results posted
Jun 2025
Primary outcome: Primary: Mild Cognitive Impairment — 25; 0; 23; 9 Participants
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- Cognitive Battery (Diagnostic_test); Voice, Speech and Language Analysis (Behavioral); Questionnaires and Clinical Assessments (Behavioral); DNA Analysis (Genetic)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- University of Massachusetts, Worcester
- Primary completion
- Sep 2023
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Mild Cognitive Impairment |
25; 0; 23; 9 | — |
| PRIMARY Mean Fundamental Frequency |
137.7; 142.4; 166.4 | — |
Summary
The Investigators aim to identify speech and language markers that provide information on cognitive function and predict cognitive decline in Parkinson's disease. The Investigators will administer speech tasks and cognitive assessments to participants with Parkinson's disease and healthy controls. The Investigators will also explore the associations between genetic factors and speech and cognitive status in Parkinson's disease.
Eligibility Criteria
Inclusion Criteria
- Parkinson's Disease (or healthy control)
- Disease duration ≥ 2 years
- Mild cognitive impairment or normal cognition
Exclusion Criteria
- Diagnosis of dementia (MoCA <21)
- Adults unable to consent
- Age < 18
- Pregnant women
- Prisoners
- Non-English speakers
- Any neurological disorder other than PD
- Deep brain stimulator placement
- Severe, unstable psychiatric disorder
- Unintelligible speech due to effects of PD
- Visual acuity or color vision impairment that would interfere with cognitive testing
- Other voice, speech or swallowing disorders or history of surgery involving palate/nasopharynx/larynx/vocal cords
Data sourced from ClinicalTrials.gov (NCT04273672). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.